- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
In the quest to turn carbon nanotubes from nanoscale wonder into clinically useful drug and imaging agent delivery agents, researchers have often added polymer coatings to the outside of the nanotubes in order to render them biocompatible. Now, researchers at Stanford University have found that even when coated, carbon nanotubes retain the ability to bind extraordinarily large numbers of drug and imaging agent molecules in a stable yet reversible manner.
Reporting its work in the journal ACS Nano, a research team led by Hongjie Dai, Ph.D., an investigator in the Center for Cancer Nanotechnology Excellence Focused on Therapy Response, showed that polymer-coated single-walled carbon nanotubes spontaneously absorbed the cancer drug doxorubicin onto their surfaces when the drug was added to the nanotubes dissolved in water. The resulting construct contained approximately 50 to 60 percent doxorubicin by weight, far higher than the 8 to 10 percent obtained with either liposomes or dendrimers.
The investigators also found that the carbon nanotubes retained their drug payload when dissolved in normal physiological buffer and blood serum, but that the drug released quickly from the nanotubes in the acidic environment characteristic of the insides of tumor cells. The investigators showed, too, that they could permanently attach tumor-targeting molecules and imaging contrast agents to the nanotubes, raising the possibility of creating multifunctional nanoscale devices that could both detect and treat tumors.
This work, which was supported by the National Cancer Institute's Alliance for Nanotechnology in Cancer, is detailed in the paper, "Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery." An abstract of this paper is available at the journal's Web site.
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Programmable materials find strength in molecular repetition May 23rd, 2016
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016